Aurobindo Pharma on Thursday said the $900 million deal to acquire Sandoz Inc’s US-based generic oral solids and dermatology businesses, has been mutually called off New Delhi: Aurobindo Pharma on Thursday said the $900 million deal to acquire Sandoz Inc’s US-based generic oral solids and dermatology businesses, has been mutually called off. “The decision was taken as approval from the …